Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Full enrollment in phase III Virulizin trial

June 21, 2004

PSMA-targeting immunotherapies presented at ASCO

June 21, 2004

Insegia chosen as trade name for G17DT

June 18, 2004

Polyvalent vaccine reported to improve survival in advanced melanoma

June 18, 2004

Pivotal phase III trial of Rencarex for renal cell carcinoma opens enrollment

June 17, 2004

Synergistic effects of IL-21 and rituximab in B-lymphoma cell lines

June 17, 2004

An EGF vaccine reported to improve survival in advanced lung cancer

June 17, 2004

Antitumor effects of CpG-7909 in several types of human cancer

June 17, 2004

Autologous Xcellerated T-cells show antitumor efficacy in phase I/II clinical trials

June 16, 2004

Preliminary data suggest epratuzumab plus rituximab is safe and effective in NHL

June 16, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...